

August 5, 2016



Company Profile for Trevena, Inc.

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines. Trevena's oliceridine is in Phase 3 development for the management of moderate to severe acute pain, and is the first pain program granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

Company: Trevena, Inc.

Headquarters Address: 1018 West 8th Ave, Suite A
King of Prussia, PA 19406

Main Telephone: 610-354-8840

Website: www.trevena.com

Ticker/ISIN: TRVN(NASDAQ)/US89532E1091

Type of Organization: Public

Industry: Biotechnology

Key Executives: **CEO:** Maxine Gowen

Investor Relations

Contact: Jonathan Violin

Phone: 610-534-8840

Email: IR@trevenainc.com

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160805005022/en/>

Source: Trevena, Inc.